When: Near or below 200 SMA at $345 where risk/reward inverts

Then: Preferred re-entry zone $340-$360

SELL with reduced sizing (0.1–0.2x benchmark) and wider stop at 355–360; do not redeploy on near-term dips

• Position sizing should be 0.1 to 0.2 times benchmark, not 0.3 to 0.5, given four concurrent catalysts (IRS audit, governance lawsuit, CMS Star Ratings, Q3 earnings) in a six-week window
• Stop loss should be set at 355 to 360 (below 200 SMA region), not 374, because ATR has compressed from 12.80 to 10.17 over the past month, creating risk of mechanical wicks taking out stops before real moves
• Forward P/E of 17x requires 22.44 EPS anchored to a 44% earnings rebound from a base deliberately depressed by extraordinary items, supported by only one quarter of evidence (Q1 2026 at 6.90 EPS)
• Revenue grew 38% from 2022 to 2025 while net income fell 40%, representing unresolved margin compression that has been paused not resolved
• Q4 2025 net income was $10 million on $113 billion in revenue, a margin collapse that Q1 2026 has not definitively reversed
• Operating income collapsed 41% from the 2023 peak, with the Q1 2026 print offering only one quarter of recovery evidence
• The 200 SMA at 345 is a stress event not a buying opportunity; if it breaks, the next reference is the 52-week low at 256, representing a 33% drawdown from current levels
• Medicare Advantage member trimming is an admission that the 2024-2025 underwriting assumptions were mispriced by a magnitude requiring strategic retreat, not evidence of management discipline
• Optum goodwill of $130 billion (42% of total assets) represents concentrated regulatory and write-down exposure; the consolidation means Optum shares the parent company's catalyst risk rather than shielding from it
• The neutral analyst's stop at 320 implicitly acknowledges 20% drawdown risk while calling the setup a buying opportunity
• Macro environment is actively against the position: Polymarket prices 86% probability of zero Fed cuts in 2026, bond selloff is resuming despite Treasury intervention, Trump is escalating economic warfare rhetoric against Iran, and crude is rising
• The aggressive analyst's bear case framing requires assumptions about IRS resolution, lawsuit discovery, CMS Star Ratings, and Q3 earnings structure — each with base rate probabilities not fully quantified
• The catalyst cluster involves four separate probability distributions that may correlate but are not guaranteed to; joint probability is not reducible to a single narrative
• Do not redeploy proceeds into UNH on any near-term dip; revisit only with a clear technical breakout above 10 EMA at 397 and ideally 50 SMA at 414 if catalysts resolve favorably
• Prior 52-week high is 461; if all catalysts resolve favorably, revisit with clear technical breakout criteria rather than catching falling knives

→ vs aggressive: Asymmetric setup framing uses trader language not risk manager language; the position sizing at 0.3–0.5x benchmark into four unresolved binary catalysts with undisclosed dollar exposure is standing in front of the blast radius, not positioning intelligently

→ vs aggressive: The bear case is not just 'continued technical deterioration' — it also requires negative IRS resolution, lawsuit discovery surfacing additional issues, CMS Star Ratings disappointment, and Q3 earnings confirming structural 2025 deterioration rather than Q1 2026 normalization; each has unquantified base rate probability

→ vs aggressive: The stop at 374 (one ATR) will be wicked out by routine noise in a compressing volatility environment before the real move begins; ATR has compressed from 12.80 to 10.17 over the past month and the technical report flags this as a setup for volatility expansion

→ vs neutral: Forward P/E of 17x is at the higher end of historical sector range, anchored to a 22.44 EPS recovery that requires a 44% earnings rebound from a deliberately depressed base, supported by only one quarter of evidence (Q1 2026 at 6.90 EPS)

→ vs neutral: The 200 SMA at 345 is a stress event not a buying opportunity; breaking it leads to 52-week low at 256, a 33% drawdown, yet the neutral analyst frames this risk as an opportunity and acknowledges it with a stop at 320

→ vs neutral: Medicare Advantage member trimming is an admission of mispriced underwriting assumptions, not margin-defensive discipline; it signals the 2024-2025 unit economics were wrong by a magnitude requiring strategic retreat

→ vs neutral: Optum is not a separate shield; its goodwill of $130 billion (42% of assets) is consolidated with the parent and becomes a write-down target if catalysts force impairment testing

→ vs neutral: Multiple expansion requires either earnings growth exceeding expectations or a discount rate compression; neither exists — earnings need to nearly double to justify current price and the macro discount rate environment is actively moving against high-multiple names

SELL (calibrated: 0.25-0.35x benchmark with stop at $368-$372)

• Aggressive analyst's 80% negative skew is narrative compression—four independent catalyst events have their own base rate probabilities and aren't guaranteed to stack into near-certain bearish
• 200 SMA at $345 is a live structural support (11.5% above current price, rising 3.5% over 7 weeks), not merely a tripwire—flush to that level without breaking it historically produces reflexive buying
• Q1 2026 data provides informational value: FCF recovered to $8.15 billion, balance sheet actively deleveraging, forward earnings implying 44% rebound
• Conservative analyst's proposed $355-$360 stop is too loose—it accepts 7-8% drawdown before exit and becomes meaningless for tail risk if gap-down occurs
• Conservative analyst's characterization of Optum diversification as 'a shield with a target painted on it' is analytically incomplete—PBM, care delivery, and analytics have different revenue mix, margin profile, and regulatory exposure than insurance underwriting
• 16-year dividend track record and $2.32 quarterly payout reflect cash generation across multiple economic cycles with stabilizing effect on multiple
• Re-entry criteria: breakout above 10 EMA at $397 with RSI reclaiming 40, OR sustained hold above 200 SMA at $345 with no positive catalyst resolution

→ vs aggressive: Joint probability of four independent catalysts all going negative is not near-certain—the 33% downside target to 52-week low at $256 is overcalibrated relative to genuine uncertainty given structural support at $345

→ vs conservative: Position sizing to 0.1-0.2x benchmark leaves material return on the table if Q1 2026 floor thesis is correct—base case isn't worst case, and sizing for absolute worst case is fear wearing a suit

→ vs conservative: Proposed stop at $355-$360 only fires after the move it was designed to avoid has already happened—ATR-compressed environment doesn't justify accepting 7-8% drawdown before exit

→ vs conservative: Calling dividend 'fully priced in' ignores how quality-income narratives function in institutional portfolio construction—dividend track record has stabilizing effect on multiple even during ugly headlines